Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CardioProtectMI

Financiado

Cerrado

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial I... ver más

29/02/2020

RESOTHER PHARMA A/...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

RESOTHER PHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-29

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

RESOTHER PHARMA A/S

50.00K€ | Lider

VERBIO TECHNOLOGIES

395.27K€ | Participante

Proyectos interesantes

CardioProtectMI

Medical Technol...

Pharmaceuticals

4M€ Cerrado

aNtHESIS

Medical Technol...

Biotechnology

150K€ Cerrado

CuRE

Medical Technol...

Biotechnology

2M€ Cerrado

BES-2015-072699

Medical Technol...

Cardiology

93K€ Cerrado

PID2019-107332RB-I00

Medical Technol...

Data Science

375K€ Cerrado

PhyCaR

Medical Technol...

Applied Physics

161K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 3 meses Fecha Inicio: 2019-11-29
Fecha Fin: 2020-02-29

Líder del proyecto

RESOTHER PHARMA AS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores